<span item_type="fundamental" item_id="ff9d8dd085c9d5a0c96d880ad3e695b5" counter_id="ST/US/REVBW" env="prod"></span><span item_type="announcement" item_id="513932132081732097" env="prod"></span><p>EPS: As of FY2025 Q1, the actual value is USD -2.11.</p><p></p><h3>Cash and Cash Equivalents</h3><ul><li>As of March 31, 2025, Revelation Biosciences, Inc. had $3.7 million in cash and cash equivalents, a decrease from $6.5 million as of December 31, 2024. This decrease was primarily due to cash used for operating activities.<span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/1810560/000095017025067043/revb-ex99_1.htm"></span></li></ul><h3>Net Cash Used for Operating Activities</h3><ul><li>Net cash used for operating activities for the three months ended March 31, 2025, was $2.8 million, consistent with the same period in 2024.<span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/1810560/000095017025067043/revb-ex99_1.htm"></span></li></ul><h3>Net Loss</h3><ul><li>The net loss for the three months ended March 31, 2025, was $2.1 million, or - $2.11 basic and diluted net loss per share, compared to a net loss of $2.7 million, or - $39.37 basic and diluted net loss per share for the same period in 2024.<span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/1810560/000095017025067043/revb-ex99_1.htm"></span></li></ul><h3>Operating Expenses</h3><ul><li>Total operating expenses for the three months ended March 31, 2025, were $2.1 million, compared to $1.9 million for the same period in 2024.<span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/1810560/000095017025067043/revb-ex99_1.htm"></span></li></ul><h3>Other Income (Expense)</h3><ul><li>Total other income (expense), net for the three months ended March 31, 2025, was $43,902, compared to - $779,295 for the same period in 2024.<span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/1810560/000095017025067043/revb-ex99_1.htm"></span></li></ul><h3>Outlook / Guidance</h3><ul><li>Revelation Biosciences, Inc. anticipates that its current cash and cash equivalents are sufficient to fund operations through June 2025.<span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/1810560/000095017025067043/revb-ex99_1.htm"></span></li></ul>

Revelation Biosciences - CW27 | 8-K: FY2025 Q1 EPS: USD -2.11